

## AngioDynamics Announces Conference Call for First Quarter FY08 Financial Results

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Sept. 17, 2007--AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it plans to report its first fiscal quarter financial results on Monday, October 1, 2007, after the close of the financial markets.

Eamonn P. Hobbs, president and chief executive officer, and Joseph Gersuk, chief financial officer, will host an investment community conference call beginning at 4:30 p.m. Eastern time on October 1st to discuss these results and to answer questions.

To participate in the live call by telephone, please dial (888) 679-8038 from the U.S., or for international callers, please dial (617) 213-4850. Please enter the passcode: 99830939.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of AngioDynamics' website at <http://investor.angiodynamics.com>. To listen to the live call, please go to the website 15 minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the website. A telephone replay will be available from 6:30 p.m. Eastern time on October 1, 2007 through 11:59 p.m. Eastern time on October 8 by dialing (888) 286-8010 (domestic) or (617) 801-6888 (international) and entering the passcode: 48003479.

### About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.

CONTACT: AngioDynamics, Inc.

D. Joseph Gersuk, CFO, 800-772-6446 x1608

[jgersuk@AngioDynamics.com](mailto:jgersuk@AngioDynamics.com)

or

EVC Group, Inc.

Jennifer Beugelmans, 646-201-5447 (Investor Relations)

[jbeugelmans@evcgroup.com](mailto:jbeugelmans@evcgroup.com)

Doug Sherk, 646-201-5447 (Investor Relations)

[dsherk@evcgroup.com](mailto:dsherk@evcgroup.com)

Steve DiMattia, 646-201-5445 (Media)

[sdimattia@evcgroup.com](mailto:sdimattia@evcgroup.com)

SOURCE: AngioDynamics, Inc.